Wire · opportunities
BofA makes bullish call on newly public biotech stock
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 29 August 2026 · Fusion42 review
Bank of America initiated coverage of Apnimed, a newly public biotech focused on a novel oral sleep apnea pill, with a Buy rating and $41 price target. The FDA decision expected by February 28, 2027, will be a critical milestone for the drug's potential market entry and adoption.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a narrow window to influence physician adoption ahead of an FDA decision that could create a new oral treatment for sleep apnea. Prepare to engage specialists who can offer early patient feedback and shape market perception.
◆ Coverage
1 source · 29 Aug 2026
◆ Related on Wire
◆ Topics